Burst CME™ – Integrating the Latest Updates for PARP Inhibitors Across Ovarian Cancer
Burst CME™ – Integrating the Latest Updates for PARP Inhibitors Across Ovarian Cancer is organized by Physicians' Education Resource, LLC (PER).
Activity Overview:
In 2022, it is estimated that there will be 19,880 new cases of ovarian cancer diagnosed in the United States, and despite advances in treatment, an estimated 12,810 women will die of the disease. Women who achieve a response to initial adjuvant chemotherapy and those with relapsed, refractory disease may be candidates for maintenance therapy. Since 2014, PARP inhibitors have been approved for maintenance therapy in patients with ovarian cancer. Importantly, the available PARP inhibitors vary in their approved indications and in their safety profiles.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of ovarian cancer in the maintenance setting, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain evidence-based recommendations in parallel with testing strategies that inform the evolving use of PARP inhibitor strategies in ovarian cancer
• Report recent clinical trial results on emerging strategies applying PARP inhibitors among patients with advanced ovarian cancer in multiple lines of therapy
• Determine treatment-related toxicities from recent clinical trials that evaluated PARP inhibitors
Additional details will be posted as soon as information is available.
